Trial: 201808015

KEYSTROKE: A RANDOMIZED PHASE II STUDY OF PEMBROLIZUMAB (KEYTRUDA®) PLUS STEREOTACTIC RE-IRRADIATION VERSUS SBRT ALONE FOR LOCOREGIONALLY RECURRENT OR SECOND PRIMARY HEAD AND NECK CARCINOMA

Phase

II

Principal Investigator

Thorstad, Wade

Disease Site

Ill-Defined Sites; Lip, Oral Cavity and Pharynx

Learn more about this study at: clinicaltrials.gov